Corpus Intelligence IC Memo — NORTH CAROLINA SPECIALTY HOSPITAL 2026-04-26 08:08 UTC
IC Memo — NORTH CAROLINA SPECIALTY HOSPITAL
Investment Committee Memorandum | NC | 18 beds | Grade C | EBITDA uplift $5.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NORTH CAROLINA SPECIALTY HOSPITAL

CCN 340049 | DURHAM, NC | 18 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NORTH CAROLINA SPECIALTY HOSPITAL is a 18-bed suburban community hospital in DURHAM, NC with $71.6M in net patient revenue and a 11.7% operating margin. The hospital serves a payer mix of 31.6% Medicare, 0.8% Medicaid, and 67.6% commercial.

Thesis: Turnaround. Our ML models identify $5.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 11.7% to 19.1% (+736bps).

Net Revenue HCRIS$71.6M
Current EBITDA COMPUTED$8.4M
Operating Margin COMPUTED11.7%
Occupancy HCRIS23.7%
Revenue / Bed COMPUTED$4.0M
Net-to-Gross HCRIS42.6%
Distress Probability ML50.6%

2. Market Context & Competitive Position

129
NC Hospitals
-2.0%
State Median Margin
28
Comparable Hospitals

NC has 129 Medicare-certified hospitals with a median operating margin of -2.0%. The target's margin of 11.7% places it above the state median. Among 28 size-comparable peers (9-36 beds), the median margin is -8.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (9-36), prioritizing same-state peers. 28 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NORTH CAROLINA SPECIALTY HOSPI (Target)NC18$71.6M11.7%
NOVANT HEALTH MINT HILL MEDICANC36$107.8M9.7%
THE OUTER BANKS HOSPITALNC21$93.7M26.2%
MEDICAL PARK HOSPITALNC22$82.6M15.8%
THE MCDOWELL HOSPITALNC30$65.7M-6.7%
CHOWAN HOSPITAL INC.NC25$61.5M10.4%
MURPHY MEDICAL CENTERNC25$58.0M-8.8%
J ARTHUR DOSHER MEMORIAL HOSPINC25$57.6M3.8%
ST LUKES HOSPITALNC25$50.4M-1.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.5M+210bp18mo
Cost to Collect4.5%2.5%$1.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$871K+122bp9mo
Clean Claim Rate88.0%96.0%$46K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.5M
Cost to Collect
$1.4M
Denial Rate Reduction
$1.4M
A/R Days Reduction
$871K
Clean Claim Rate
$46K
Total EBITDA Uplift$5.3M
Current EBITDA$8.4M
+ RCM Uplift+$5.3M
Pro Forma EBITDA$13.7M
Current Margin11.7%
Pro Forma Margin19.1%
WC Released (1x)$2.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$12.9M$108.0M8.37x52.9%
Base (11x exit)10.0x11.0x$12.9M$123.0M9.53x57.0%
Bull Case9.0x11.0x$11.6M$144.6M12.45x65.6%
Bull (12x exit)9.0x12.0x$11.6M$161.1M13.87x69.2%
Bear Case11.0x10.0x$14.2M$77.5M5.46x40.4%
Bear (11x exit)11.0x11.0x$14.2M$89.8M6.33x44.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 23.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 28 hospitals with 9-36 beds
  • Same-state prioritization (n=29)
  • Comp margins: P25=-21.4% / P50=-8.8% / P75=2.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.